Posted by Michael Wonder on 14 Dec 2020
Novartis receives EU approval for Leqvio (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year
11 December 2020 - Leqvio (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol lowering treatment in Europe.
Novartis announced today that the European Commission has approved Leqvio (inclisiran) for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
This approval is based on the results of the robust ORION clinical development program, where Leqvio provided an effective and sustained low-density lipoprotein cholesterol (LDL-C) reduction of up to 52% in patients with elevated LDL-C, despite maximally tolerated statin therapy.
